SG Americas Securities LLC acquired a new position in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,945 shares of the biotechnology company’s stock, valued at approximately $146,000.
A number of other institutional investors also recently made changes to their positions in RGNX. PNC Financial Services Group Inc. raised its position in REGENXBIO by 73.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 746 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of REGENXBIO during the first quarter valued at about $56,000. Headlands Technologies LLC increased its holdings in shares of REGENXBIO by 276.8% in the first quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock worth $81,000 after buying an additional 2,812 shares during the period. Diversified Trust Co bought a new stake in shares of REGENXBIO in the 2nd quarter valued at about $121,000. Finally, ProShare Advisors LLC lifted its stake in shares of REGENXBIO by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 874 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.
REGENXBIO Price Performance
RGNX stock opened at $9.35 on Friday. The firm has a 50-day moving average of $11.10 and a 200 day moving average of $13.05. The company has a market cap of $460.54 million, a P/E ratio of -1.59 and a beta of 1.21. REGENXBIO Inc. has a 1 year low of $9.11 and a 1 year high of $28.80.
Analysts Set New Price Targets
A number of equities analysts have commented on RGNX shares. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Raymond James reaffirmed an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a research note on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a report on Wednesday, September 4th. Barclays cut their price target on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Tuesday. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.45.
Check Out Our Latest Stock Report on REGENXBIO
Insiders Place Their Bets
In other news, Director Argeris N. Karabelas sold 11,000 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.04, for a total value of $165,440.00. Following the sale, the director now directly owns 11,286 shares of the company’s stock, valued at $169,741.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Argeris N. Karabelas sold 11,000 shares of REGENXBIO stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $165,440.00. Following the completion of the transaction, the director now directly owns 11,286 shares in the company, valued at approximately $169,741.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at $114,101.46. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,848 shares of company stock worth $665,197. 13.13% of the stock is owned by corporate insiders.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
- Five stocks we like better than REGENXBIO
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Texas Roadhouse Stock Steering for New Highs This Year
- Investing in the High PE Growth Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Best Fintech Stocks for a Portfolio Boost
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.